**JoVE54541**

**TITLE:** A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantitate

Neurodegenerative Biomarkers and Apolioprotein E Isoform Status

**AUTHORS:** 1Heywood Wendy E, 1Baud Anna, 1Bliss Emily, 1Sirka Ernestas, 2Schott Jonathan M, 3Zetterberg Henrik, 4Galimberti Daniela, 5Sebire Neil J and 1Mills Kevin

1Centre for Translational Omics, Genetics and Genomic Medicine Dept, UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH UK

2Dementia Research Centre, Institute of Neurology, Queen Square, UCL, London, UK

3Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, 431 80 Mölndal, Sweden

4Neurology Unit, Dept. of Pathophysiology and Transplantation, University of Milan, Fondazione Cà Granda, IRCCS Ospedale Policlinico, Via F.Sforza 35 20122 Milan, Italy

5Great Ormond Street Hospital for Children, London WC1N 3JH, UK

[wendy.heywood@ucl.ac.uk](mailto:wendy.heywood@ucl.ac.uk), Baud, Anna [a.baud@ucl.ac.uk](mailto:a.baud@ucl.ac.uk), Bliss, Emily [emily.bliss.10@ucl.ac.uk](mailto:emily.bliss.10@ucl.ac.uk), Sirka, Ernestas [e.sirka@ucl.ac.uk](mailto:e.sirka@ucl.ac.uk), Schott, Jonathan [j.schott@ucl.ac.uk](mailto:j.schott@ucl.ac.uk)

, Zetterberg, Henrik [h.zetterberg@ucl.ac.uk](mailto:h.zetterberg@ucl.ac.uk) Daniela Galimberti [daniela.galimberti@unimi.it](mailto:daniela.galimberti@unimi.it) Neil Sebire [Neil.Sebire@gosh.nhs.uk](mailto:Neil.Sebire@gosh.nhs.uk) Kevin Mills, kevin.mills@ucl.ac.uk

**CORRESPONDING AUTHOR:** Dr Kevin Mills, kevin.mills@ucl.ac.uk, Tel +44(0)207 905 2873

We hereby give JoVE permission to re-print figure Figure 4. Example data. And table 2 which are taken from our previous publication 1

1 Heywood, W. E. *et al.* Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. *Mol Neurodegener.* **10** 64, doi:10.1186/s13024-015-0059-y, (2015).

Kind regards

Dr Kevin Mills